Contineum Therapeutics, Inc. $CTNM Stock Position Reduced by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. cut its stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 46.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,221 shares of the company’s stock after selling 12,144 shares during the period. Goldman Sachs Group Inc. owned about 0.05% of Contineum Therapeutics worth $99,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Strs Ohio acquired a new stake in Contineum Therapeutics in the first quarter valued at approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Contineum Therapeutics by 90.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company’s stock valued at $86,000 after acquiring an additional 2,783 shares during the last quarter. Bank of America Corp DE lifted its stake in Contineum Therapeutics by 63.4% in the fourth quarter. Bank of America Corp DE now owns 9,132 shares of the company’s stock valued at $134,000 after acquiring an additional 3,542 shares during the last quarter. Nuveen LLC acquired a new stake in Contineum Therapeutics in the first quarter valued at approximately $93,000. Finally, Nuveen Asset Management LLC acquired a new stake in Contineum Therapeutics in the fourth quarter valued at approximately $195,000.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $11.82 on Tuesday. Contineum Therapeutics, Inc. has a 52 week low of $3.35 and a 52 week high of $20.24. The company’s fifty day moving average is $9.16 and its 200-day moving average is $6.23. The company has a market capitalization of $331.43 million, a PE ratio of -5.37 and a beta of 1.13.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, analysts forecast that Contineum Therapeutics, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

CTNM has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. Leerink Partners initiated coverage on shares of Contineum Therapeutics in a research note on Thursday, September 25th. They issued an “outperform” rating and a $20.00 price objective for the company. William Blair initiated coverage on shares of Contineum Therapeutics in a research note on Friday, June 20th. They issued an “outperform” rating for the company. Finally, Leerink Partnrs upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Thursday, September 25th. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $22.20.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).